Top Markets
Coin of the day
Sanofi Sanofi

Sanofi

SNY
Rank in Stocks #179
Sanofi, together with its subsidiaries, engages in the research, development,... Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Share Price
$44.60
Market Cap
$108.62B
Change (1 day)
-1.63%
Change (1 year)
-21.62%
Country
FR
Trade Sanofi (SNY)

Category

P/E ratio for Sanofi (SNY)
P/E ratio as of March 2026 TTM: 8.78
According to Sanofi latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 8.78. At the end of 2024 the company had a P/E ratio of 21.10.
P/E ratio history for Sanofi from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 8.78 -32.02%
2025 12.92 -38.76%
2024 21.10 1.40%
2023 20.81 54.85%
2022 13.44 -24.64%
2021 17.83 122.16%
2020 8.02 -79.90%
2019 39.92 82.18%
2018 21.91 -5.40%
2017 23.16 10.24%
2016 21.01 -12.27%
2015 23.95 5.61%
2014 22.68 -17.39%
2013 27.45 44.75%
2012 18.97 43.94%
2011 13.18 -8.09%
2010 14.34 4.92%
2009 13.66 65.17%
2008 8.27 -48.59%
2007 16.09 -32.21%
2006 23.74 -45.86%
2005 43.84 -317.87%
2004 -20.12 -199.40%
2003 20.24 -15.94%
2002 24.08 -37.41%
2001 38.47 -26.60%
2000 52.42 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
42.86 388.04%
US
28.47 224.13%
GB
21.88 149.17%
US
92.55 953.80%
US
20.85 137.40%
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.